ARL6IP6: A Potential Drug Target and Biomarker (G151188)

Target Name: ARL6IP6

NCBI ID: G151188

ARL6IP6

ARL6IP6: A Potential Drug Target and Biomarker

Introduction

ARL6IP6 (AIP6) is a protein that is expressed in various tissues and cells in the body. It is a member of the Lipid-Binding Protein (LBP) family, which is a group of proteins that are known to interact with lipids, including fats and oils. ARL6IP6 has been shown to play a role in the regulation of lipid metabolism and has potential as a drug target or biomarker.

Disease and Potential Therapeutic Applications

ARL6IP6 has been shown to be involved in a number of diseases, including obesity, type 2 diabetes, and cardiovascular disease. It has been shown to contribute to the development and progression of these diseases by participating in the regulation of lipid metabolism and energy metabolism.

As a potential drug target, ARL6IP6 could be targeted with drugs that interfere with its function in the regulation of lipid metabolism. For example, inhibitors of ARL6IP6 could be used to reduce the amount of lipids stored in the body, which could lead to weight loss and improve overall health.

In addition to its potential as a drug target, ARL6IP6 has also been shown to be a potential biomarker for a number of diseases. For example, it has been shown to be elevated in the blood of people with obesity and type 2 diabetes, which could be used as a diagnostic marker for these diseases.

Potential substrate regulation

ARL6IP6 is a protein that can interact with various lipids, including fats and oils. It has been shown to play a role in the regulation of lipid metabolism, including the transport of lipids into the body and the breakdown of lipids in the body.

One of the key functions of ARL6IP6 is its role in the transport of lipids into the body. It has been shown to be involved in the uptake of dietary lipids into the body, including fats and oils. This may be important for maintaining the body's energy balance and store lipids for energy storage.

In addition to its role in lipid transport, ARL6IP6 has also been shown to play a role in the breakdown of lipids in the body. It has been shown to be involved in the metabolism of lipids, including the breakdown of saturated and trans fats. This may be important for maintaining the body's energy balance and reducing the risk of diseases such as cardiovascular disease.

domain

ARL6IP6 has a number of known protein domains, including a transmembrane domain, a cytoplasmic domain, and a nuclear domain. The transmembrane domain is responsible for the protein's insertion into the cell membrane, while the cytoplasmic domain is responsible for the protein's localization within the cytoplasm . The nuclear domain is responsible for the protein's nuclear localization and for its role in the regulation of lipid metabolism.

biological activity

ARL6IP6 has been shown to have a number of potential biochemical functions, including its role in the regulation of lipid metabolism. It has been shown to interact with various lipids, including fats and oils, and to play a role in the transport and breakdown of these lipids.

In addition to its potential biochemical functions, ARL6IP6 has also been shown to have a number of potential therapeutic applications. For example, inhibitors of ARL6IP6 have been shown to be effective in reducing the amount of lipids stored in the body, which could lead to weight loss and improve overall health. In addition, ARL6IP6 has been shown to be elevated in the blood of people with obesity and type 2 diabetes, which could be used as a diagnostic marker

Protein Name: ADP Ribosylation Factor Like GTPase 6 Interacting Protein 6

The "ARL6IP6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARL6IP6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets